Medical World News® After Hours: Oncologist Amy Comander, MD, Discusses Marathon Running and Motivation

Video

During an After Hours segment of Medical World News®, Amy Comander, MD, spoke about her passion for marathon running and how it helps keep her inspired in her work as an oncologist.

A recent ‘Narratives in Oncology’ article written for The Oncologist journal details the experience of physician and marathon runner Amy Comander, MD, with the 124th Boston Marathon. Like most events scheduled in 2020, the marathon was canceled due to the COVID-19 pandemic. In her narrative, Comander discusses gratitude and resilience in times of uncertainty, explaining how the running community has helped her remember to keep her head up.

In addition, Comander has helped organize fundraising races, like the PAVING Program 5K, a virtual 5k to be held June 4 through 6, 2021.

CancerNetwork® sat down with Comander, of the Mass General Cancer Center in Waltham and Harvard Medical School, to talk about what marathon running means to her and her plans for participating in future races.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

References

1. Comander A. Remember Your Why: An Oncologist's Reflections on Running During the COVID-19 Pandemic. Oncologist. 2021;26(4):348-349. doi:10.1002/onco.13683

Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
The Together for Supportive Cancer Care coalition may advance the national conversation in ensuring comprehensive care for all patients with cancer.
Health care organizations have come together to form the Together for Supportive Cancer Care coalition to address gaps in supportive cancer care services.
Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.